Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Egualen SCHEMBL10805301 | 0.99 | FABP3 (0.38) | FABP3FABP4FABP5HDAC4HDAC8 | |
| Egualen SCHEMBL442214 | 0.99 | FABP3 (0.38) | FABP3FABP4FABP5HDAC4HDAC8 | |
| Egualen SCHEMBL14482099 | 0.97 | FABP3 (0.37) | FABP3FABP4FABP5HDAC4HDAC8 | |
| SCHEMBL10804152 | 0.90 | FABP3 (0.36) | FABP3FABP4FABP5HDAC4HDAC8 | |
| SCHEMBL10803865 | 0.89 | FABP3 (0.36) | FABP3FABP4FABP5HDAC4HDAC8 | |
| SCHEMBL10810406 | 0.88 | ELANE (0.36) | FABP3FABP4FABP5HDAC4HDAC8 | |
| SCHEMBL7787569 | 0.87 | FABP3 (0.36) | FABP3FABP4FABP5HDAC4HDAC8 | |
| SCHEMBL10803313 | 0.87 | ELANE (0.36) | FABP3FABP4FABP5HDAC4HDAC8 | |
| SCHEMBL10810625 | 0.87 | ELANE (0.38) | — | |
| SCHEMBL10803533 | 0.86 | ELANE (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160250217-A1 | CRYSTALLINE FORM OF PEMIROLAST | RSPR PHARMA AB (SE) | 2016-09-01 | — | — | US | claimed |
| CN-102596202-B | Crystalline forms of pemirolast | CARDOZ AB | 2015-01-21 | — | — | CN | claimed |
| US-20120329813-A1 | Pemirolast for the Treatment of Systemic Low Grade Inflammation | CARDOZ AB (SE) | 2012-12-27 | — | — | US | claimed |
| CN-102724982-A | PEMIROLAST FOR THE TREATMENT OF SYSTEMIC LOW GRADE INFLAMMATION | CARDOZ AB | 2012-10-10 | — | — | CN | claimed |
| EP-2498779-A1 | PEMIROLAST FOR THE TREATMENT OF SYSTEMIC LOW GRADE INFLAMMATION | Cardoz AB (SE) | 2012-09-19 | — | — | EP | claimed |
| CN-102596202-A | Novel crystalline forms of pemirolast | CARDOZ AB | 2012-07-18 | — | — | CN | claimed |
| US-20120157415-A1 | New Crystalline Form of Pemirolast | CARDOZ AB (SE) | 2012-06-21 | — | — | US | claimed |
| WO-2010146348-A9 | CRYSTALLINE FORM OF PEMIROLAST | CARDOZ AB (SE) | 2012-05-03 | — | — | WO | claimed |
| EP-2443120-A2 | NEW CRYSTALLINE FORM OF PEMIROLAST | Cardoz AB (SE) | 2012-04-25 | — | — | EP | claimed |
| WO-2011058331-A1 | PEMIROLAST FOR THE TREATMENT OF SYSTEMIC LOW GRADE INFLAMMATION | CARDOZ AB (SE) | 2011-05-19 | — | — | WO | claimed |
| WO-2010146348-A2 | NEW CRYSTALLINE FORM OF PEMIROLAST | CARDOZ AB (SE) | 2010-12-23 | — | — | WO | claimed |
| WO-2010146341-A2 | NEW CRYSTALLINE FORM OF PEMIROLAST | CARDOZ AB (SE) | 2010-12-23 | — | — | WO | claimed |
| WO-2009007679-A2 | COMBINATION FOR USE IN THE TREATMENT OF ATHEROSCLEROSIS COMPRISING A MAST CELL INHIBITOR AND A THROMBOXANE A2 ANTAGONIST | CARDOZ AB (SE) | 2009-01-15 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0147915-B1 | NEW AZULENE DERIVATIVES USEFUL AS ANTI-ULCERATIVE AND ANTI-FLAMMATORY AGENTS | Kotobuki Seiyaku Co., Ltd. (JP) | 1987-05-06 | — | — | EP | claimed |
| JP-4295419-A | — | — | None | — | — | JP | disclosed |
| WO-2025124483-A1 | ORAL DRUG DOSAGE FORM FOR TARGETED DRUG DELIVERY BASED ON TRACKING MARKER AND METHODS OF DESIGN AND USE THEREOF | Triastek, Inc. (CN) | 2025-06-19 | — | — | WO | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| JP-H04295419-A | ABSORPTION-ACCELERATING AGENT | NIPPON SHINYAKU CO LTD | 1992-10-20 | — | — | JP | disclosed |
| US-4595694-A | Peptic ulcer treatment | KOTOBUKI SEIYAKU CO. LTD. (JP) | 1986-06-17 | — | — | US | disclosed |